Rxivist logo

Molecular Screening of Familial Hypercholesterolemia in the Icelandic Population

By Greg Kellogg, Bolli Thorsson, Ying Cai, Robert Wisotzkey, Andrew Pollock, Matthew Akana, Rebecca Fox, Michael Jansen, Elias F. Gudmundsson, Bonny Patel, Chihyu Chang, Malgorzata Jaremko, Valur Emilsson, Vilmundur Gudnason, Oscar Puig

Posted 27 Sep 2018
bioRxiv DOI: 10.1101/425975

Familial hypercholesterolemia (FH) is a monogenic disease characterized by a lifelong exposure to high LDL-C levels that can lead to early onset coronary heart disease (CHD). The main causes of FH identified to date include loss-of-function mutations in LDLR or APOB, or gain-of-function mutations in PCSK9. Early diagnosis and genetic testing of FH suspects is critical for improved prognosis of affected individuals as lipid lowering treatments are effective in preventing CHD related morbidity and mortality. In the present manuscript, we developed a comprehensive next generation sequencing (NGS) panel which we applied on two different resources of FH in the Icelandic population: 62 subjects from 23 FH families with known or unknown culprit mutations, and a population-based sampling of 315 subjects selected for total cholesterol levels above the 95th percentile cut-point. The application of the NGS panel revealed significant diagnostic yields in identifying pathogenic LDLR mutations in both family and population-based genetic testing.

Download data

  • Downloaded 413 times
  • Download rankings, all-time:
    • Site-wide: 38,946 out of 89,091
    • In genetics: 2,286 out of 4,610
  • Year to date:
    • Site-wide: 57,339 out of 89,091
  • Since beginning of last month:
    • Site-wide: 45,402 out of 89,091

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News